Slide 1: Q3 Earning Call
Q 3 Earning Call 12 November 2021
Slide 2: Safe Harbor Statement
S a fe H a r b o r S tate m e nt This presentation contains “forward-looking statements” within the meaning of the conduct of its clinical trials as well as significant increased expenditures; Compugen’s Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the business mod
Slide 3: Anat Cohen-Dayag, President and CEO
Anat Cohen-Dayag , President and CEO
Slide 4: Long-term strategy
L o n g - te r m st rate g y Advance Expand Maximize Protect Immuno-oncology research Number of patients Value for patients Intellectual Property responding to treatment Excellence in Focus on patients non- Strategic collaborations Seek broad IP protection immuno-oncology & responsive or refractory
Slide 5: Comprehensive clinical strategy targeting DNAM pathways
C o m p re h e n s i ve c l i n i c a l st rate g y ta rget i n g D N A M p at hway s Multiple combination studies, biomarker informed tumor types selection and translational data analytics to direct future path forward PROGRAM TARGET PARTNER BIOMARKER INFORMED EXPANSION COHORTS IN SELECT TUMORS STA
Slide 6: Well executed milestone rich year
We l l exe c u te d m i l e sto n e r i c h 2 0 2 1 Striding forward as leaders in the DNAM axis space Expected date Program Milestone Achieved COM701 mono Phase 1 dose escalation and expansion Data presented H1 2021 COM701+ nivolumab Phase 1 dose escalation Data presented COM701 + nivolumab Phase 1
Slide 7: COM701, nivolumab and BMS-986207 well tolerated in dose escalation study
CO M 7 0 1 , n i vo l u m a b a n d B M S - 9 8 6 2 0 7 c o m b i n at i o n we l l to l e rate d i n d o s e e s c a l at i o n st u d y 20 mg/kg Prostate cancer 113 Favorable safety and 10 mg/kg Gastric cancer 111 0.3 mg/kg Ovarian cancer 75*† tolerability 3 mg/kg NSCLC 63 1 mg/kg CRC 58* COM701 D
Slide 8: Potent activation of the immune system with COM701, nivolumab and BMS-986207 triple blockade
Po te nt a c t i vat i o n o f t h e i m m u n e sy ste m w i t h CO M 7 0 1 , n i vo l u m a b a n d B M S - 9 8 6 2 0 7 t r i p l e b l o c ka d e Increased T and NK cell activation, memory T Cell proliferation and IFNg induction in blood at all COM701 doses A 24 Avr. Fold Change=2.7 P=<0.0001 ***
Slide 9: COM902 monotherapy well tolerated in dose escalation study
CO M 9 0 2 m o n o t h e ra p y we l l to l e rate d i n d o s e e s c a l at i o n st u d y 1 mg/kg Chordoma 344† Favorable safety and 0.01 mg/kg Adenoid-cystic CA trachea 302† 0.01 mg/kg 291 tolerability 1 mg/kg Rectal CA Ovarian CA 131 0.1 mg/kg Peritoneal CA 83† 1 mg/kg Appendiceal CA 83* 10 mg/
Slide 10: COM902 avoids depletion of major TIGIT+ expressing lymphocytes
CO M 9 0 2 avo i d s d e p l et i o n o f m a j o r T I G I T + ex p re s s i n g l y m p h o c y te s - N K , C D 4 a n d C D 8 T c e l l s Supporting rationale for selecting high affinity COM902 as a IgG4 reduced Fc effector function CD4+ Naive CD8+ Naive CD4+ CM CD8+ CM 100 CD4+ EM CD8+ EM CD4+ E
Slide 11: Compugen leadership in the DNAM Axis space
C o m p u ge n l e a d e rs h i p i n t h e D N A M A x i s s p a c e Strong execution of a differentiated clinical strategy PVRIG TIGIT 1. Only Company targeting PVRIG, TIGIT and PD-1 TIGIT+ PVRIG 4. Only Company targeting TIGIT + PVRIG in a PD-1 combinations in the clinic as part of our three- PD-
Slide 12: Strong cash position to fund progress
S t ro n g c a s h p o s i t i o n to f u n d p ro g re s s CASH BALANCE GROSS CASH EXPENDITURES (EXCLUDES ANY POTENTIAL CASH INFLOWS) • ~$102 million as of September 30, 2021 • Cash balance at year end expected to • 2021 expected gross cash be in the range of $113- $116 expenditures ~$40 million •